®
150 mg/mL ANTIMICROBIAL NADA 141-328, Approved by FDA For subcutaneous injection in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.
(gamithromycin)
Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. READ ENTIRE BROCHURE CAREFULLY BEFORE USING THIS PRODUCT.
INDICATIONS ZACTRAN is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non-lactating dairy cattle. ZACTRAN is also indicated for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with Mannheimia haemolytica and Pasteurella multocida.
CONTRAINDICATIONS As with all drugs, the use of ZACTRAN is contraindicated in animals previously found to be hypersensitive to this drug.
WARNING: FOR USE IN CATTLE ONLY. NOT FOR USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN. NOT FOR USE IN CHICKENS OR TURKEYS. The material safety data sheet (MSDS) contains more detailed occupational safety information. To report adverse effects, obtain an MSDS or for assistance, contact Merial at 1-888-637-4251.
RESIDUE WARNINGS: Do not treat cattle within 35 days of slaughter. Because a discard time in milk has not been established, do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.
PRECAUTIONS The effects of ZACTRAN on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection of ZACTRAN may cause a transient local tissue reaction in some cattle that may result in trim loss of edible tissues at slaughter.
ADVERSE REACTIONS Transient animal discomfort and mild to moderate injection site swelling may be seen in cattle treated with ZACTRAN.
EFFECTIVENESS The effectiveness of ZACTRAN for the treatment of BRD associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni was demonstrated in a field study conducted at four geographic locations in the United States. A total of 497 cattle exhibiting clinical signs of BRD were enrolled in the study. Cattle were administered ZACTRAN (6 mg/kg BW) or an equivalent volume of sterile saline as a subcutaneous injection once on Day 0. Cattle were observed daily for clinical signs of BRD and were evaluated for clinical success on Day 10. The percentage of successes in cattle treated with ZACTRAN (58%) was statistically significantly higher (p<0.05) than the percentage of successes in the cattle treated with saline (19%). The effectiveness of ZACTRAN for the treatment of BRD associated with M. bovis was demonstrated independently at two U.S. study sites. A total of 502 cattle exhibiting clinical signs of BRD were enrolled in the studies. Cattle were administered ZACTRAN (6 mg/ kg BW) or an equivalent volume of sterile saline as a subcutaneous injection once on Day 0. At each site, the percentage of successes in cattle treated with ZACTRAN on Day 10 was statistically significantly higher than the percentage of successes in the cattle treated with saline (74.4% vs. 24% [p <0.001], and 67.4% vs. 46.2% [p = 0.002]). In addition, in the group of calves treated with gamithromycin that were confirmed positive for M. bovis (pre-treatment nasopharyngeal swabs), there were more calves at each site (45 of 57 calves, and 5 of 6 calves) classified as successes than as failures. The effectiveness of ZACTRAN for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica and Pasteurella multocida was demonstrated in two independent studies conducted in the United States. A total of 467 crossbred beef cattle at high risk of developing BRD were enrolled in the study. ZACTRAN (6 mg/kg BW) or an equivalent volume of sterile saline was administered as a single subcutaneous injection within one day after arrival. Cattle were observed daily for clinical signs of BRD and were evaluated for clinical success on Day 10 post-treatment. In each of the two studies, the percentage of successes in the cattle treated with ZACTRAN (86% and 78%) was statistically significantly higher (p = 0.0019 and p = 0.0016) than the percentage of successes in the cattle treated with saline (36% and 58%).
Marketed by Merial Limited 3239 Satellite Blvd., Duluth, GA 30096-4640 U.S.A. Made in Austria
®ZACTRAN is a registered trademark of Merial Limited. ©2012 Merial Limited. All rights reserved. Rev. 03/2012
tioneer know what’s been done to add value to that animal, such as “the herd health program you have in place, all the value-added prac- tices that you’ve done like castrating and dehorning, and if you’ve done any third-party verifi cation types of things with your vaccination pro- gram, like a Vac 45,” Nichols says. The owner also needs to make sure the auctioneer conveys that infor- mation to potential buyers. That’s one of the differences be-
tween preparing cattle for auction and raising them for a private treaty buyer. You know which programs the private buyer wants you to fol- low. You don’t know exactly who the bidders are at auction or what they’re looking for. Breed is one characteristic. De
Cordova says at Buffalo, “any An- gus-sired calf, or Charolais-cross calf” will most likely to fetch a higher price at this time. He says buyers also look for cattle from a producer who’s built a reputation around good genetics and/or health programs. But at Buffalo’s regular Saturday
auctions, they don’t look for much else. “We don’t see the added value in the price increase on the weekly sale for the calves that have had those shots that we do in what we call weaned calf sales,” de Cordova says. “On our weekly sale markets, most of our cattle have never had hands laid on them. They won’t be cut. They’ve never had any kind of a shot. That’s just kind of a normal procedure, and that’s the way a lot of the sales in this part of the country are. People will just go get
enough calves that they’re ready to sell.” That’s more common than not,
says Dr. Ron Gill, Texas A&M AgriL- ife Extension livestock specialist and professor of animal science. “Preparing them hasn’t been a high priority a lot of times,” he says. “When they think it’s time to mar- ket, a lot of people just pull them off the cows and go straight to pens. It’s kind of a diffi cult situation to try to tell a producer he probably ought to wean those calves at home and try to prepare them for market for at least 21 days at a minimum, preferably 45, before you market them, when you have that high-cost feed resource and everything else going into that process.” But ideally, says Gill, before they
go to market the calves should be weaned and moved onto grass or hay. The hope is to minimize their stress from separation anxiety and to get them to maintain a 1- to 1.5-pound per day gain during the weaning phase. “Then,” he says, “when they go
to market, those calves will not shrink that much, and you can al- most pay for your backgrounding program on shrink management. That’s a very diffi cult thing to con- vey to someone who doesn’t think about shrink in those terms, but we see quite a bit of difference in shrink in calves that are weaned at home and then taken to the market.” There’s a penalty for failure to
wean well in advance of the sale. A calf pulled off its mother and taken immediately to town will normally shrink 8 to 10 percent. “They’re not
Expect just-weaned calves to shrink 8 to 10 percent.
ZACTRAN-PI-thirdpage-MBovis_THE
CATTLEMAN_FA.indd 11/3/13 11:38 AM 44 The Cattleman July 2013
thecattlemanmagazine.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94